

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase...
Q2 2026
Aug 13, 2026
Q1 2026
May 7, 2026
FY 2025
Mar 30, 2026
Q4 2025
Mar 30, 2026
Q3 2025
Nov 10, 2025